Physical activity and its mechanistic effects on prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 3, 2015, Pages 197-207

  Wekesa, A ^a   Harrison, M ^b   Watson, R W ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b South East Technological University   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR; ANDROSTANOLONE; CASPASE; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; FOLLISTATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBIN; INHIBIN B; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPID; MYOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; SMAD PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER;

ADIPOSE TISSUE; AEROBIC EXERCISE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGRESSION; CANCER RISK; CARCINOGENESIS; EVIDENCE BASED PRACTICE; HORMONE ACTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT RESPONSE; WALKING; ANIMAL; COMPLICATION; IMMUNOLOGY; INCIDENCE; MALE; METABOLISM; MORTALITY; MOTOR ACTIVITY; PROSTATIC NEOPLASMS; RISK FACTOR;

ANIMALS; BIOMARKERS; HUMANS; INCIDENCE; INFLAMMATION; MALE; MORTALITY; MOTOR ACTIVITY; PROSTATIC NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84939264095     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.9     Document Type: Review

References (125)

1. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009; 53: 171-184.
2. GLOBOCAN. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer (World Health Organization).
3. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-1413.
4. World Health Organization (WHO). Global Strategy on Diet, Physical Activity and Health, 2004.
5. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 1985; 100: 126-131.
6. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104: 815-840.
7. Fong DY, Ho JW, Hui BP, Lee AM, Macfarlane DJ, Leung SS et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ 2012; 344: e70.
8. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A et al. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2006; 56: 254-281 quiz 313-254.
9. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002; 132 (11 Suppl): 3456S-3464S.
10. Pierotti B, Altieri A, Talamini R, Montella M, Tavani A, Negri E et al. Lifetime physical activity and prostate cancer risk. Int J Cancer 2005; 114: 639-642.
11. Nilsen TI, Romundstad PR, Vatten LJ. Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer 2006; 119: 2943-2947.
12. Darlington GA, Kreiger N, Lightfoot N, Purdham J, Sass-Kortsak A. Prostate cancer risk and diet, recreational physical activity and cigarette smoking. Chronic Dis Can 2007; 27: 145-153.
13. Lagiou A, Samoli E, Georgila C, Minaki P, Barbouni A, Tzonou A et al. Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia. Eur J Cancer Prev 2008; 17: 336-339.
14. Littman A, Kristal A, White E. Recreational physical activity and prostate cancer risk (United States). Cancer Causes Control 2006; 17: 831-841.
15. Krishnadasan A, Kennedy N, Zhao Y, Morgenstern H, Ritz B. Nested case-control study of occupational physical activity and prostate cancer among workers using a job exposure matrix. Cancer Causes Control 2008; 19: 107-114.
16. Moore SC, Peters TM, Ahn J, Park Y, Schatzkin A, Albanes D et al. Age-specific physical activity and prostate cancer risk among white men and black men. Cancer 2009; 115: 5060-5070.
17. Antonelli JA, Jones LW, Banez LL, Thomas JA, Anderson K, Taylor LA et al. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol 2009; 182: 2226-2231.
18. Johnsen NF, Tjonneland A, Thomsen BL, Christensen J, Loft S, Friedenreich C et al. Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer 2009; 125: 902-908.
19. Orsini N, Bellocco R, Bottai M, Pagano M, Andersson SO, Johansson JE et al. A prospective study of lifetime physical activity and prostate cancer incidence and mortality. Br J Cancer 2009; 101: 1932-1938.
20. Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Res 2011; 71: 3889-3895.
21. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncolo 2011; 29: 726-732.
22. Singh AA, Jones LW, Antonelli JA, Gerber L, Calloway EE, Shuler KH et al. Association between exercise and primary incidence of prostate cancer: does race matter Cancer 2013; 119: 1338-1343.
23. Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC. A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 2005; 165: 1005-1010.
24. Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev 2005; 14: 275-279.
25. Jian L, Shen ZJ, Lee AH, Binns CW. Moderate physical activity and prostate cancer risk: a case-control study in China. Eur J Epidemiol 2005; 20: 155-160.
26. Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG. Case-control study of lifetime total physical activity and prostate cancer risk. Am J Epidemiol 2004; 159: 740-749.
27. Wiklund F, Lageros YT, Chang E, Balter K, Johansson JE, Adami HO et al. Lifetime total physical activity and prostate cancer risk: a population-based case-control study in Sweden. Eur J Epidemiol 2008; 23: 739-746.
28. Zeegers MP, Dirx MJ, van den Brandt PA. Physical activity and the risk of prostate cancer in the Netherlands cohort study, results after 9.3 years of follow-up. Cancer Epidemiol Biomarkers Prev 2005; 14: 1490-1495.
29. Magbanua MJ, Richman EL, Sosa EV, Jones LW, Simko J, Shinohara K et al. Physical activity and prostate gene expression in men with low-risk prostate cancer. Cancer Causes Control 2014; 25: 515-523.
30. Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol 2013; 14: 1112-1120.
31. Rundqvist H, Augsten M, Stromberg A, Rullman E, Mijwel S, Kharaziha P et al. Effect of acute exercise on prostate cancer cell growth. PLoS One 2013; 8: e67579.
32. Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. Eur J Cancer Prev 2007; 16: 415-421.
33. Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol 2004; 96: 450-454.
34. Soliman S, Aronson WJ, Barnard RJ. Analyzing serum-stimulated prostate cancer cell lines after low-fat, high-fiber diet and exercise intervention. Evid Based Complement Altern Med 2011; 2011: 529053.
35. Mina DS, Connor MK, Alibhai SM, Toren P, Guglietti C, Matthew AG et al. Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study. Can Urol Assoc J 2013; 7: E692-E698.
36. Loprinzi PD, Richart SM. White blood cell counts mediate the effects of physical activity on prostate-specific antigen levels. Res Q Exerc Sport 2014; 85: 409-413.
37. Teixeira GR, Favaro WJ, Pinheiro PF, Chuffa LG, Amorim JP, Mendes LO et al. Physical exercise on the rat ventral prostate: steroid hormone receptors, apoptosis and cell proliferation. Scand J Med Sci Sports 2012; 22: e86-e92.
38. Colbert LH, Visser M, Simonsick EM, Tracy RP, Newman AB, Kritchevsky SB et al. Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004; 52: 1098-1104.
39. Ford ES. Does exercise reduce inflammation Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002; 13: 561-568.
40. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001; 153: 242-250.
41. Gueritat J, Lefeuvre-Orfila L, Vincent S, Cretual A, Ravanat JL, Gratas-Delamarche A et al. Exercise training combined with antioxidant supplementation prevents the antiproliferative activity of their single treatment in prostate cancer through inhibition of redox adaptation. Free Radic Biol Med 2014; 77: 95-105.
42. McCullough DJ, Nguyen LM, Siemann DW, Behnke BJ. Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. J Appl Physiol (1985) 2013; 115: 1846-1854.
43. Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D et al. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol (1985) 2012; 113: 263-272.
44. Murphy EA, Davis JM, Barrilleaux TL, McClellan JL, Steiner JL, Carmichael MD et al. Benefits of exercise training on breast cancer progression and inflammation in C3(1)SV40Tag mice. Cytokine 2011; 55: 274-279.
45. Esser KA, Harpole CE, Prins GS, Diamond AM. Physical activity reduces prostate carcinogenesis in a transgenic model. Prostate 2009; 69: 1372-1377.
46. Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ, Lin Y et al. Inhibitory effect of voluntary running wheel exercise on the growth of human pancreatic Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice. Oncol Rep 2008; 19: 1583-1588.
47. Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 2010; 9: 2482-2496.
48. Catoire M, Mensink M, Kalkhoven E, Schrauwen P, Kersten S. Identification of human exercise-induced myokines using secretome analysis . Physiol Genomics 2014; 46: 256-267.
49. Penkowa M, Keller C, Keller P, Jauffred S, Pedersen BK. Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 2003; 17: 2166-2168.
50. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 2000; 529(Pt 1): 237-242.
51. Schoenfeld B. Potential mechanisms for a role of metabolic stress in hypertrophic adaptations to resistance training. Sports Med 2013; 43: 179-194.
52. Catoire M, Mensink M, Boekschoten MV, Hangelbroek R, Muller M, Schrauwen P et al. Pronounced effects of acute endurance exercise on gene expression in resting and exercising human skeletal muscle. PLoS One 2012; 7: e51066.
53. Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 1987; 237: 402-405.
54. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
55. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537-1545.
56. Mavros Y, Kay S, Anderberg KA, Baker MK, Wang Y, Zhao R et al. Changes in insulin resistance and HbA1c are related to exercise-mediated changes in body composition in older adults with type 2 diabetes: interim outcomes from the GREAT2DO trial. Diabetes Care 2013; 36: 2372-2379.
57. Thompson D, Karpe F, Lafontan M, Frayn K. Physical activity and exercise in the regulation of human adipose tissue physiology. Physiol Rev 2012; 92: 157-191.
58. Jakicic JM. The effect of physical activity on body weight. Obesity (Silver Spring) 2009; 17 (Suppl 3): S34-S38.
59. Ronn T, Volkov P, Davegardh C, Dayeh T, Hall E, Olsson AH et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet 2013; 9: e1003572.
60. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005; 174: 1065-1070.
61. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMPactivated protein kinase. Cancer Prev Res (Phila) 2008; 1: 369-375.
62. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001; 86: 1341-1345.
63. Tymchuk CN, Barnard RJ, Ngo TH, Aronson WJ. Role of testosterone, estradiol, and insulin in diet-and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr Cancer 2002; 42: 112-116.
64. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 1998; 31: 127-131.
65. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate 2003; 56: 201-206.
66. Cadore EL, Kruel LFM. Acute and Chronic Testosterone Responses to Physical Exercise and Training. In: Dubey R (ed). Sex Hormones. InTech: Rijeka, Croatia, 2012, pp 442.
67. Hsing AW, Chua S Jr., Gao YT, Gentzschein E, Chang L, Deng J et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93: 783-789.
68. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 2002; 50: 1-3.
69. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-566.
70. Hellenius ML, Brismar KE, Berglund BH, de Faire UH. Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. J Intern Med 1995; 238: 121-130.
71. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow Lancet 2001; 357: 539-545.
72. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005; 95: 961-962.
73. Kleinclauss F, Gigante M, Neuzillet Y, Mouzin M, Terrier N, Salomon L et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 2374-2380.
74. Joseph R, Bockorny B, Dasanu CA. Methotrexate therapy leading to a rapid progression of a previously indolent prostate cancer: is immunosuppression to blame J Oncol Pharm Pract 2014; 20: 149-153.
75. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 2005; 45: 1563-1569.
76. Campbell KL, McTiernan A. Exercise and biomarkers for cancer prevention studies. J Nutr 2007; 137 (1 Suppl): 161S-169S.
77. Woods JA, Vieira VJ, Keylock KT. Exercise, inflammation, and innate immunity. Neurol Clin 2006; 24: 585-599.
78. Jankord R, Jemiolo B. Influence of physical activity on serum IL-6 and IL-10 levels in healthy older men. Med Sci Sports Exerc 2004; 36: 960-964.
79. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 2003; 17: 884-886.
80. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett 2003; 90: 103-122.
81. Nieman DC. Exercise immunology: practical applications. Int J Sports Med 1997; 18 (Suppl 1): S91-S100.
82. Fairey AS, Courneya KS, Field CJ, Mackey JR. Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. Cancer 2002; 94: 539-551.
83. Kruijsen-Jaarsma M, Revesz D, Bierings MB, Buffart LM, Takken T. Effects of exercise on immune function in patients with cancer: a systematic review. Exerc Immunol Rev 2013; 19: 120-143.
84. Hansen J, Brandt C, Nielsen AR, Hojman P, Whitham M, Febbraio MA et al. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology 2011; 152: 164-171.
85. Jakob H, Anders R, Claus B, Peter P. Activin A suppression during acute exercise. Endo: The Endocrine Society: San Franscisco, CA, USA, 2013.
86. Safarinejad MR, Azma K, Kolahi AA. The effects of intensive, long-term treadmill running on reproductive hormones, hypothalamus-pituitary-testis axis, and semen quality: a randomized controlled study. J Endocrinol 2009; 200: 259-271.
87. Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc 2010; 42: 2023-2029.
88. Hulmi JJ, Ahtiainen JP, Kaasalainen T, Pollanen E, Hakkinen K, Alen M et al. Postexercise myostatin and activin IIb mRNA levels: effects of strength training. Med Sci Sports Exerc 2007; 39: 289-297.
89. Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008; 294: E918-E927.
90. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387: 83-90.
91. Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999; 180: 1-9.
92. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002; 277: 49831-49840.
93. Lee S-J, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci 2001; 98: 9306-9311.
94. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002; 277: 40735-40741.
95. Luisi S, Florio P, Reis FM, Petraglia F. Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol 2001; 145: 225-236.
96. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H et al. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 2009; 7: 15.
97. Gregory SJ, Kaiser UB. Regulation of gonadotropins by inhibin and activin. Semin Rreprod Med 2004; 22: 253-267.
98. Burger HG, Igarashi M. Inhibin: definition and nomenclature, including related substances. Endocrinology 1988; 122: 1701-1702.
99. Ying SY. Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 1988; 9: 267-293.
100. Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M et al. TGF signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-1014.
101. Mathews L, Vale W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991; 65: 973-982.
102. Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL. Human follistatinrelated protein: a structural homologue of follistatin with nuclear localization. Endocrinology 2001; 142: 3426-3434.
103. Miyazono K. Positive and negative regulation of TGF-beta signaling. J Cell Sci 2000; 113 (Pt 7): 1101-1109.
104. Bilezikjian LM, Blount AL, Donaldson CJ, Vale WW. Pituitary actions of ligands of the TGF-beta family: activins and inhibins. Reproduction 2006; 132: 207-215.
105. Thomas TZ, Wang H, Niclasen P, O'Bryan MK, Evans LW, Groome NP et al. Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 1997; 82: 3851-3858.
106. Thomas TZ, Chapman SM, Hong W, Gurusingfhe C, Mellor SL, Fletcher R et al. Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. Prostate 1998; 34: 34-43.
107. Anderson RA, Evans LW, Irvine DS, McIntyre MA, Groome NP, Riley SC. Follistatin and activin A production by the male reproductive tract. Hum Reprod 1998; 13: 3319-3325.
108. Cancilla B, Jarred RA, Wang H, Mellor SL, Cunha GR, Risbridger GP. Regulation of prostate branching morphogenesis by activin A and follistatin. Dev Biol 2001; 237: 145-158.
109. Risbridger GP. Recent progress in our understanding of inhibin in the prostate gland. J Endocrinol 1998; 157: 1-4.
110. Havard M, Dautry F, Tchenio T. A dormant state modulated by osmotic pressure controls clonogenicity of prostate cancer cells. J Biol Chem 2011; 286: 44177-44186.
111. Liu Y, Cheng H, Zhou Y, Zhu Y, Bian R, Chen Y et al. Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cells. Cell Death Dis 2013; 4: e494.
112. Wang Q, Tabatabaei S, Planz B, Lin CW, Sluss PM. Identification of an activinfollistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells. J Urol 1999; 161: 1378-1384.
113. Mellor SL, Richards MG, Pedersen JS, Robertson DM, Risbridger GP. Loss of the expression and localization of inhibin alpha-subunit in high grade prostate cancer. J Clin Endocrinol Metab 1998; 83: 969-975.
114. Draper LB, Matzuk MM, Roberts VJ, Cox E, Weiss J, Mather JP et al. Identification of an inhibin receptor in gonadal tumors from inhibin alpha-subunit knockout mice. J Biol Chem 1998; 273: 398-403.
115. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 2000; 404: 411-414.
116. Gao X, Wei S, Lai K, Sheng J, Su J, Zhu J et al. Nucleolar follistatin promotes cancer cell survival under glucose-deprived conditions through inhibiting cellular rRNA synthesis. J Biol Chem 2010; 285: 36857-36864.
117. Lyssiotis CA, Vander-Heiden MG, Munoz-Pinedo C, Emerling BM. Emerging concepts: linking hypoxic signaling and cancer metabolism. Cell Death Dis 2012; 3: e303.
118. Gao X, Hu H, Zhu J, Xu Z. Identification and characterization of follistatin as a novel angiogenin-binding protein. FEBS Lett 2007; 581: 5505-5510.
119. Li S, Ibaragi S, Hu GF. Angiogenin as a molecular target for the treatment of prostate cancer. Curr Cancer Ther Rev 2011; 7: 83-90.
120. Ye L, Lewis-Russell JM, Kynaston H, Jiang WG. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 2007; 178 (Pt 1): 1086-1091.
121. Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stemlike cells in bone. J Exp Med 2011; 208: 2641-2655.
122. Najy AJ, Day KC, Day ML. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res 2008; 68: 1092-1099.
123. Simon DP, Vadakkadath Meethal S, Wilson AC, Gallego MJ, Weinecke SL, Bruce E et al. Activin receptor signaling regulates prostatic epithelial cell adhesion and viability. Neoplasia 2009; 11: 365-376.
124. McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer 2008; 8: 205-211.
125. Thompson PD, Buchner D, Pinã IL, Balady GJ, Williams MA, Marcus BH et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a Statement From the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109-3116.